M & As this week: ImmunoPrecise Antibodies, Ergomed
Canadian antibody development and production services provider ImmunoPrecise Antibodies plans to acquire Netherlands-based contract research organisation QVQ Holding (QVQ) for C$0.74m ($0.59m). (Source: Drug Development Technology)
Source: Drug Development Technology - October 5, 2017 Category: Pharmaceuticals Source Type: news

Deals this week: Ixaltis, Arbutus Biopharma, Gesynta Pharma
French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases. (Source: Drug Development Technology)
Source: Drug Development Technology - October 5, 2017 Category: Pharmaceuticals Source Type: news

Adynxx closes patient enrolment in Phase II trial of post-surgical pain treatment brivoligide
US-based biotechnology firm Adynxx has completed patient enrolment in a Phase II trial (ADYX-004) of its lead product candidate, brivoligide (AYX1), for reducing acute pain and preventing chronic pain following total knee replacement surgery. (Source: Drug Development Technology)
Source: Drug Development Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news

Melior begins dosing MLR-1023 in Phase IIb trial to treat type 2 diabetes
US-based Melior Pharmaceuticals I has begun dosing in a Phase IIb trial aimed at evaluating the efficacy of MLR-1023, an oral insulin sensitizer, in adult patients with uncontrolled type 2 diabetes on metformin therapy. (Source: Drug Development Technology)
Source: Drug Development Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news

Achieve begins multi-dose study of cytisine for smoking cessation
US-based specialist pharmaceutical firm Achieve Life Sciences has begun a multi-dose study to evaluate both pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of cytisine, a plant-based alkaloid with a high-binding affinity to the nicotini … (Source: Drug Development Technology)
Source: Drug Development Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news

Ablynx's trial of aTTP treatment caplacizumab shows positive results
Belgian company Ablynx has reported positive topline results from the Phase III HERCULES trial with caplacizumab to treat acquired thrombotic thrombocytopenic purpura (aTTP). (Source: Drug Development Technology)
Source: Drug Development Technology - October 3, 2017 Category: Pharmaceuticals Source Type: news

AOBiome starts patient enrolment in Phase Ib/IIa trial to treat allergic rhinitis
US-based life sciences firm AOBiome has started enrolling patients in a Phase Ib/IIa clinical trial of its ammonia oxidising bacteria (AOB) product candidate to treat seasonal allergic rhinitis (SAR). (Source: Drug Development Technology)
Source: Drug Development Technology - October 3, 2017 Category: Pharmaceuticals Source Type: news

ImmunoMet begins Phase I cancer trial of OXPHOS Inhibitor IM156
US-based biotechnology firm ImmunoMet Therapeutics has started its Phase I clinical trial for IM156, a potent oxidative phosphorylation (OXPHOS) inhibitor to treat patients with solid tumours.     (Source: Drug Development Technology)
Source: Drug Development Technology - October 3, 2017 Category: Pharmaceuticals Source Type: news

Seres reports positive Phase Ib trial results of SER-287 in UC patients
US-based Seres Therapeutics has reported positive topline results from a Phase Ib placebo-controlled induction trial of SER-287 in patients with mild-to-moderate ulcerative colitis (UC), who were failing current therapies. (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

Eisai reports positive Phase III trial data of Lenvima for liver cancer
Eisai has reported positive results from analysis of the subpopulation of subjects in the Greater China region participating in its Phase III REFLECT clinical trial of lenvatinib mesylate (Lenvima) to treat unresectable hepatocellular carcinoma (HCC) … (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

SELLAS and Merck to begin Phase I/II cancer combination clinical trial
Biopharmaceutical firm SELLAS Life Sciences Group has entered a clinical trial collaboration and supply agreement with Merck to conduct a combination clinical trial targeting multiple cancer types.   (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2017 Category: Pharmaceuticals Source Type: news

bluebird bio starts treatment in Phase I trial for multiple myeloma
bluebird bio has started treating patients in a Phase I clinical trial (CRB-402) of its investigational candidate bb21217 for relapsed or refractory multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Abivax ’s ABX464 found to reduce HIV viral reservoir in blood
Abivax has reported positive top-line data from the first cohort of Phase IIa ABX464-005 clinical trial of its drug candidate ABX464 in patients with HIV. (Source: Drug Development Technology)
Source: Drug Development Technology - October 1, 2017 Category: Pharmaceuticals Source Type: news

Noxopharm initiates Phase Ib trial of NOX66 for prostate cancer
Australia-based Noxopharm has initiated a Phase Ib clinical trial of NOX66 in metastatic castrate-resistant prostate cancer patients who do not have remaining standard therapeutic options. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news

Chiasma begins enrolment in Phase III trial for acromegaly
Chiasma has started patient enrolment in Phase III CHIASMA OPTIMAL clinical trial of its product candidate Mycapssa (octreotide capsules) as a maintenance therapy to treat adults with acromegaly. (Source: Drug Development Technology)
Source: Drug Development Technology - September 28, 2017 Category: Pharmaceuticals Source Type: news